Polyrizon Ltd. (PLRZ), a development-stage biotech company, has filed a divisional patent application with the Israel Patent Office for its Trap & Target or T&T intranasal drug delivery platform.
The T&T platform is designed to enhance the bioavailability and effectiveness of active pharmaceutical ingredients or APIs by increasing their residence time in the nasal cavity and improving their absorption.
This technology addresses key challenges in both local and systemic drug delivery, making it suitable for a wide range of therapeutic applications, such as respiratory conditions, central nervous system disorders, and opioid overdose treatment.
The filing represents Polyrizon's ongoing efforts to protect its intellectual property and strengthens the company's position in the field of advanced nasal drug delivery.
The T&T platform boasts features like prolonged residence time, controlled release, and improved bioavailability, while also being compatible with various drug types including small molecules, proteins, and peptides.
This application complements the company's recent U.S. patent filing, which covers Polyrizon's two core technologies: Trap & Target or T&T and Capture and Contain or C&C, a nasal blocker platform.
"We are excited to continue expanding our intellectual property portfolio with the filing of this divisional patent application," said Tomer Izraeli, CEO of Polyrizon. "The T&T platform has the potential to revolutionize intranasal drug delivery and improve patient outcomes across multiple therapeutic areas."
PLRZ closed Thursday's (Jan.30 2025) trading at $1.32 up by 1.53%. In premarket trading on Friday, the stock is down 6.82% at $1.23.
For comments and feedback: editorial@rttnews.com